Clinical Trial Update: MD1003-AMN MD1003 in Adrenomyeloneuropathy [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial MD1003 for Adrenomyeloneuropathy and Adrenoleukodystrophy has completed Phase 2/Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenoleukodystrophy
• Adrenomyeloneuropathy

Drugs mentioned

• MD1003 (biotin (high-dose))

Snippet

Sponsor: MedDay Pharmaceuticals SA | Conditions: Adrenomyeloneuropathy, Adrenoleukodystrophy | Phase 2, Phase 3 | Status: COMPLETED